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Edited by Gerrit van MeerAbstract Eight distinct inherited disorders have been linked to
diﬀerent enzyme defects in the isoprenoid/cholesterol biosyn-
thetic pathway following the ﬁnding of abnormally increased lev-
els of intermediate metabolites in patients and conﬁrmed by the
demonstration of disease-causing mutations in genes encoding
the implicated enzymes. Patients aﬄicted with these disorders
are characterized by multiple morphogenic and congenital anom-
alies including internal organ, skeletal and/or skin abnormalities
underlining an important role for cholesterol in human embryo-
genesis and development. The etiology of the underlying patho-
physiology may involve multiple aﬀected processes due to
lowered cholesterol and/or the elevated, teratogenic levels of
the intermediate sterol precursors.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cholesterol is an important structural component of cellular
membranes and myelin, and precursor of oxysterols, steroid
hormones and bile acids. Cells acquire cholesterol either by
de novo synthesis or via the uptake of low density lipoprotein
particles that contain esteriﬁed cholesterol. The identiﬁcation
of a number of inherited disorders due to a defect in choles-
terol biosynthesis has made clear that cholesterol plays a cru-
cial role in human embryogenesis and development. Currently,
eight distinct inherited disorders have been linked to diﬀerent
enzyme defects in the cholesterol biosynthetic pathway after
the ﬁnding of abnormally increased levels of intermediate
metabolites in patients followed by the demonstration of dis-
ease-causing mutations in genes encoding the implicated
enzymes. Patients aﬄicted with these disorders are character-
ized by multiple morphogenic and congenital anomalies
including internal organ, skeletal and/or skin abnormalities.
Although the genetic causes underlying these defects are
known, the etiology of the pathophysiology associated with
the defects remains unclear and may involve multiple aﬀected
processes due to the lowered cholesterol and/or elevated, tera-
togenic levels of intermediate sterol precursors.*Fax: +31 20 6962596.
E-mail address: h.r.waterham@amc.uva.nl (H.R. Waterham).
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Cholesterol is synthesized via the isoprenoid biosynthetic
pathway, which produces numerous biomolecules, called iso-
prenoids, that function in a variety of important cellular pro-
cesses including cell growth and diﬀerentiation, protein
glycosylation, signal transduction pathways and mitochon-
drial electron transport [1]. Isoprenoid biosynthesis starts
with the C2 compound acetyl-CoA, which by means of 6 sub-
sequent enzyme reactions is converted into isopentenyl-PP,
the basic C5 isoprene unit used for synthesis of all subsequent
isoprenoids (Fig. 1). The ﬁrst intermediate committed exclu-
sively to the production of sterol isoprenoids is C30 squalene
(composed of 6 isoprene units), which after cyclization is con-
verted into C30 lanosterol (4,4,14a-trimethylcholesta-8(9),24-
dien-3b-ol). For the generation of C27 cholesterol from
lanosterol, a series of at least 8 diﬀerent enzyme reactions
is required, including one demethylation at C-14, two deme-
thylations at C-4, one isomerization of the D8(9) double bond
to D7, three reductions of the D24, D14 and D7 double bonds,
and one desaturation between C-5 and C-6 (Fig. 2). Because
most of the cholesterogenic enzymes (or enzyme complexes)
can handle diﬀerent sterol intermediates as is also clear from
the sterol intermediates that accumulate in the various bio-
synthesis defects (see below), the sequence of the enzyme
steps involved in the conversion of lanosterol into cholesterol
may vary dependent on the tissue in which they occur. In
general, however, two major routes for cholesterol biosyn-
thesis have been proposed which depend on the timing of
reduction of the D24 double bond and postulate either 7-dehy-
drocholesterol (cholesta-5,7-dien-3b-ol) or desmosterol (cho-
lesta-5,7-dien-3b-ol) as the ultimate precursor of cholesterol
(Fig. 2). The majority of human genes encoding the enzymes
involved in post-squalene cholesterol biosynthesis have been
identiﬁed only recently though the identiﬁcation and elucida-
tion of the biochemical and molecular basis of inherited de-
fects thereof [2,3].3. Localization of isoprenoid/cholesterol biosynthesis
Except for HMG-CoA reductase, all enzymes involved in
the conversion of acetyl-CoA to farnesyl pyrophosphate, are
localized in the cytosol. HMG-CoA reductase and most of
the enzymes involved in cholesterol synthesis are localized in
the endoplasmic reticulum (ER) [1,4]. In addition, few of the
cholesterogenic enzymes are also (i.e. sterol D8(9)-isomerase)blished by Elsevier B.V. All rights reserved.
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Fig. 1. Isoprenoid biosynthesis. The isoprenoid biosynthetic pathway produces numerous biologically active compounds, i.e. isoprenoids, involved in
a variety of important cellular processes including the ones indicated in the green boxes. The enzyme mevalonate kinase (red solid bar) is deﬁcient in
patients aﬀected with mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome.
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nuclear membrane. Since 1985, a series of reports have claimed
that many of the enzymes (or the reactions they catalyze) of the
presqualene segment of the pathway are partly, mainly, or
even exclusively located in peroxisomes, whereas several en-
zymes involved in cholesterol synthesis were reported to be
colocalized in peroxisomes and in the ER. Although since then
many conﬂicting reports on this topic appeared, these studies
led to the postulation that peroxisomes would be directly in-
volved in isoprenoid/cholesterol biosynthesis (reviewed in
[1,5]). More recent studies have questioned the experimental
approaches based upon which this postulation was based
[1,5–7]. Indeed, in most cases the claim of a peroxisomal colo-
calization was based on (a) the ﬁnding of only (very) minor
amounts of proteins in enriched peroxisomal fractions ob-
tained after subcellular fractionation of rat liver tissue, (b)
immunocytochemical localization studies using antisera of
undeﬁned speciﬁcity, and/or (c) the results of overexpression
studies with tagged proteins or (portions of) proteins fused
to reporter proteins in cell lines. When combining all available
data with emphasis on studies toward the subcellular localiza-
tion of endogenous proteins under physiological conditions, it
should be concluded that there is little, if any, evidence for adirect peroxisomal involvement in the isoprenoid/cholesterol
biosynthesis.4. Defects in isoprenoid/cholesterol biosynthesis
Eight diﬀerent inherited disorders have been linked to spe-
ciﬁc enzyme defects in cholesterol biosynthesis after the ﬁnding
of abnormally increased levels of intermediate metabolites in
tissues, body ﬂuids and/or cultured cells of patients followed
by the demonstration of disease-causing mutations in genes
encoding the implicated enzymes [3].
Two disorders, classic mevalonic aciduria (MIM 251170)
and the hyperimmunoglobulinemia D and periodic fever syn-
drome (HIDS; MIM 260920) are both due to a deﬁciency of
the enzyme mevalonate kinase albeit to diﬀerent degrees due
to speciﬁc mutations in the MVK gene [8]. Cells of patients
with the HIDS presentation invariably have a residual MK en-
zyme activity of up to 10% of control values, but in cells of pa-
tients with the mevalonic aciduria presentation the activity is
below detection level. This diﬀerence is reﬂected in the high
levels of MK’s substrate mevalonic acid in plasma and urine
of patients with the mevalonic aciduria presentation and low
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Fig. 2. Cholesterol biosynthesis. After cyclization of squalene (composed of six isoprene units) lanosterol is synthesized, which is converted into
cholesterol in a series of enzyme reactions requiring one demethylation at C-14, two demethylations at C-4, one isomerization of the D8(9) double
bond to D7, three reductions of the D24, D14 and D7 double bonds, and one desaturation between C-5 and C-6. Indicated are the two major routes
involved in cholesterol synthesis. In this segment of the pathway six inherited disorders have been linked to speciﬁc enzyme deﬁciencies (indicated by
red solid bars). Numbering of the enzymes: 1, squalene synthase; 2, squalene epoxidase; 3, 2,3-oxidosqualene sterol cyclase; 4, sterol D24-reductase
(desmosterolosis); 5, sterol C-14 demethylase; 6, sterol D14-reductase (HEM dysplasia); 7, sterol C-4 demethylase complex (including a 3b-
hydroxysteroid dehydrogenase defective in CHILD syndrome); 8, sterol D8-D7 isomerase (CDPX2); 9, sterol D5-desaturase (lathosterolosis); 10, sterol
D7-reductase (SLO syndrome).
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presentation. Although originally deﬁned as two distinct syn-
dromes, they are now recognized as the severe and mild presen-
tation of one defect, named mevalonate kinase deﬁciency.
Because mevalonate kinase functions early in the pathway,the synthesis of all isoprenoids is aﬀected, although even in se-
verely aﬀected patients cholesterol levels are still low normal
(reviewed in [8]). Patients with mevalonate kinase deﬁciency
characteristically present with recurrent episodes of high fever
associated with abdominal pain, vomiting and diarrhoea,
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and skin rash, and, in severe cases, may present with additional
symptoms such as mental retardation, failure to thrive, ataxia,
cerebellar atrophy, hypotonia and dysmorphic features [9,10].
The remaining six enzyme defects exclusively aﬀect sterol
synthesis and involve four autosomal recessive and two X-
linked dominant inherited syndromes. In general, patients af-
ﬂicted with these defects present with multiple congenital,
developmental and morphogenic anomalies, including internal
organ, skeletal and/or skin abnormalities, and/or a marked de-
lay in psychomotor development underlining cholesterol’s piv-
otal role in human embryogenesis and development.
The most common defect of cholesterol biosynthesis is auto-
somal recessive Smith–Lemli–Opitz syndrome (SLOS; MIM
270400), a multiple malformation syndrome caused by 3b-
hydroxysterol D7-reductase deﬁciency (mutations in the
DHCR7 gene at 11q13). The deﬁciency results in low choles-
terol and elevated levels of 7-dehydrocholesterol (cho-
lesta-5,7-dien-3b-ol) and its isomer 8-dehydrocholesterol
(cholesta-5,8(9)-dien-3b-ol) in plasma, cells and tissues from
these patients. Patients with SLOS often present with a large
and variable spectrum of morphogenic and congenital anoma-
lies, including dysmorphic craniofacial features, microcephaly,
multiple internal organ, limb/skeletal, and urigenital malfor-
mations, (intrauterine) growth and mental retardation, and
behavioral problems [11].
Desmosterolosis (MIM 602398) and lathosterolosis (MIM
607330) are two autosomal recessive cholesterol biosynthesis
defects with a rather similar clinical presentation as SLOS,
but for each of which so far only two patients have been re-
ported. Desmosterolosis is caused by mutations in the
DHCR24 gene at 1p31.1-p33 causing a deﬁciency of 3b-
hydroxysterol D24-reductase resulting in low cholesterol and
elevated levels of desmosterol [12]. Lathosterolosis is caused
by mutations in the SC5D gene (at 11q23.3) causing a deﬁ-
ciency of 3b-hydroxysterol D5-desaturase, resulting in low cho-
lesterol and elevated levels of lathosterol in plasma, tissue and
cultured cells [13,14].
Autosomal recessive Greenberg skeletal dysplasia (MIM
215140), also known as HEM skeletal dysplasia, is rare severe
cholesterol biosynthesis defect that leads to early in utero
lethality. Aﬀected fetuses are characterized by fetal hydrops,
short-limb dwarﬁsm with an unusual ‘moth-eaten’ appearance
of the shortened long bones, bizarre ectopic ossiﬁcation centers
and disorganization of chondro-osseous histology. The defect
is caused by mutations in the LBR gene at 1q42 causing a deﬁ-
ciency of the lamin B receptor [15], which functions as the 3b-
hydroxysterol D14-reductase, resulting in elevated levels of
cholesta-8,14-dien-3b-ol and cholesta-8,14,24-trien-3b-ol in tis-
sues or cultured cells. Heterozygosity for a mutation in the
lamin B receptor gene results in Pelger–Huet anomaly (MIM
169400), a rare benign autosomal dominant disorder of leuko-
cyte development characterized by hypolobulated nuclei and
abnormal chromatin structure in granulocytes of heterozygous
individuals [16].
The two X-linked dominant inherited disorders Conradi-
Hu¨nermann–Happle syndrome (CDPX2; MIM 302960) [23]
and CHILD syndrome (MIM 308050) are caused by deﬁcien-
cies of sterol D8-D7 isomerase (mutations in the EBP gene at
Xp11.22-23) [17,18] and/or a sterol C-4 demethylase (muta-
tions in the NSDHL gene at Xq28) [19], respectively. Most
CDPX2 patients have normal cholesterol levels but elevatedplasma levels of cholesta-8(9)-en-3b-ol and, to a lesser extent,
cholesta-s5,8(9)-dien-3b-ol (8-dehydrocholesterol). Patients
with CHILD syndrome may accumulate 4-methyl sterols and
to a lesser extent 4,4 0-dimethyl sterols and 4-carboxy sterols,
but these are usually not detected. Patients with CDPX2 or
CHILD syndrome, most of whom are female, clinically present
with skeletal and skin abnormalities, including chondrodyspla-
sia punctata (epiphysic stippling), shortening of long bones,
ichtyosis and hyperkeratosis. In CDPX2, the expression of
these abnormalities is bilateral and asymmetric, while in
CHILD syndrome the expression is unilateral and most fre-
quently aﬀecting the right side of the body [20].
Although accumulation of lanosterol has been described in a
few patients diagnosed with Antley–Bixler syndrome, suggest-
ing a defect of lanosterol C14-demethylase, no mutations in
CYP51, the gene encoding lanosterol C14-demethylase were
identiﬁed. In stead it appeared that the reduced activity of this
enzyme (as well as enzymes of steroidogenesis) results from
mutations in the POR gene encoding cytochrome P450 oxido-
reductase [21].5. Regulation of isoprenoid/cholesterol biosynthesis
The rate-controlling step of the isoprenoid/cholesterol bio-
synthesis pathway is catalysed by HMG-CoA reductase, the
enzyme activity of which is controlled by multiple regulatory
mechanisms. These include regulation at gene transcriptional
level, eﬃciency of mRNA translation, rate of protein degrada-
tion and modulation of enzymatic activity [1].
Transcriptional regulation of the HMG-CoA reductase gene
occurs via feedback regulation in response to sterol levels and
is mediated by two members of the sterol regulatory element
binding protein (SREBP) family, i.e. SREBP2 and SREBP-
1a. SREBPs are transcription factors synthesized as large inac-
tive precursors located in the ER membrane where they are
tightly associated with the SREBP-cleavage-activating protein
(SCAP) escort protein [22,23]. At high sterol concentrations,
SCAP interacts strongly with one of two highly similar Insig
proteins, which causes the SREBP–SCAP complex to retain
within the ER compartment. At low sterol concentrations,
the interaction is weakened allowing the SREBP–SCAP com-
plex to transfer to the Golgi apparatus, where cleavage be-
tween the N-terminal DNA binding/transcription activation
domain and the C-terminal transmembrane/regulatory domain
of SREBP occurs, mediated by the subsequent action of two
Golgi-bound proteases S1P and S2P. The N-terminal domain
is then translocated to the nucleus where it transcriptionally
activates target genes containing sterol regulatory element se-
quences, including the HMG-CoA reductase gene, the LDL
receptor gene as well as many other genes involved in isopren-
oid/cholesterol biosynthesis [22,23]. The sterol-dependent
translocation of the SREBP–SCAP complex to the Golgi
apparatus is dependent on a functional sterol-sensing domain
in the SCAP protein, which binds directly to cholesterol, caus-
ing a conformational change of SCAP enabling the interaction
with Insig [24]. This sterol-sensing domain is a conserved mem-
brane-bound region encompassing 5 predicted membrane-
spanning helices with short intervening loops, which has been
found in several proteins that all have some relation to sterol
homeostasis. Although 25-hydroxycholesterol does not di-
rectly bind the sterol-sensing domain of SCAP, it also induces
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with Insig [24].
HMG-CoA reductase also contains a sterol-sensing domain,
which at high sterol concentrations binds sterols and one of the
Insig proteins. In this case the binding leads to ubiquitination
and proteasomal degradation of HMG-CoA reductase [25].
The ubiquitination is speciﬁcally stimulated by lanosterol,
the ﬁrst sterol intermediate in cholesterol biosynthesis, oxygen-
ated derivatives thereof or oxysterols such as 25-hydroxyster-
ols, whereas cholesterol has no stimulating eﬀect [26]. This
indicates that hydroxyl groups in the side chain and methyl
groups at the C4 and/or C14 position are key determinants
for the sterol-regulated degradation of HMG-CoA reductase.
The sterol-accelerated degradation of HMG-CoA reductase
is enhanced by non-sterol isoprenoids, including derivatives
from farnesyl pyrophosphate (e.g. farnesol) and geranylgera-
nyl pyrophosphate [25,27].
Interestingly, lanosterol does not bind the sterol-sensing do-
main of SCAP and, accordingly, does not suppress the pro-
cessing of SREBP [26]. Thus, oxysterols (derived by
conversion of cholesterol) may downregulate HMG-CoA
reductase by increased ubiquitination-mediated degradation
as well as suppression of HMG-CoA reductase gene transcrip-
tion by blocking the exit of the SREBP–SCAP complex from
the ER, whereas lanosterol selectively increases the HMG-
CoA reductase degradation rate, and cholesterol selectively
blocks the translocation of SREBP–SCAP. This conﬁrms ear-
lier data suggesting that lanosterol is the key intermediate and
its methylation the rate-limiting step in sterol synthesis. More-
over, the above discussed mechanisms imply that while lanos-
terol inhibits its own synthesis through downregulation of
HMG-CoA reductase, its overaccumulation is prevented be-
cause the transcription of the genes encoding the subsequent
cholesterol synthetic enzymes remains unaﬀected, owing to
lanosterol’s inability to suppress SREBP processing [26].
Expression of HMG-CoA reductase is also regulated at the
translational level, where the translation rate of HMG-CoA
reductase mRNA is dictated by the cells’ demand for non-ste-
rol isoprenoids. When mevalonate production by HMG-CoA
reductase is blocked by statins, HMG-CoA reductase mRNA
is translated eﬃciently even in the presence of sterols, but when
also the non-sterol requirements are fulﬁlled by the addition of
mevalonate, the translation rate reduces ﬁvefold [28].
Finally, the catalytic activity of HMG-CoA reductase can be
downregulated via phosphorylation by the AMP-dependent
kinase under inﬂuence of the cellular energy state (ATP/
AMP ratio) [29].6. Regulation of isoprenoid/cholesterol biosynthesis in
cholesterol biosynthesis defects
As already indicated, patients with mevalonate kinase deﬁ-
ciency in general have normal or low normal levels of choles-
terol implying that despite the decreased mevalonate kinase
activities these patients still are capable of generating suﬃcient
isoprenoid end products. In part this is reﬂected in the in-
creased activity of HMG-CoA reductase in cells of these pa-
tients which compensates for the decreased ﬂux [8]. However,
whereas the ﬂux through the pathway may be suﬃcient under
normal conditions it has been postulated that the pathophysi-
ology associated with this defect is due to the inability to re-spond rapidly and adequately to an instant further decrease
in the activity of mevalonate kinase leading to a (temporary)
shortage of a non-sterol-isoprenoid dependent factor required
to repress a massive inﬂammatory response [8].
The female patients aﬀected with one of the two X-linked
dominant defects also usually have normal to low normal cho-
lesterol and total sterol levels, which can be explained by the
X-chromosome inactivation pattern, which gives rise to cells
expressing the mutant allele as well as cells expressing the nor-
mal allele.
Most of the remaining autosomal recessive cholesterol bio-
synthesis defects are not only associated with low cholesterol
but also with low total sterol concentrations, indicating a dis-
turbed regulation of sterol biosynthesis most probably caused
by the accumulating sterol intermediate.
One possible scenario to explain the decreased total sterol
levels is that the sterol intermediates inhibit SREBP process-
ing, which would result in a lowered transcription of genes in-
volved in sterol synthesis. However, although desmosterol was
shown to bind to the sterol sensing domain of SCAP in vitro
and induces the same conformational change of SCAP as cho-
lesterol [30], the sterol intermediates lanosterol, zymosterol,
zymostenol, lathosterol, 7-dehydrocholesterol, and also des-
mosterol do not inhibit SREBP processing in intact cells [26]
and thus do not exert a more potent feedback regulation via
SREBP. This is also conﬁrmed by the mRNA levels of the
SREBP-responsive HMG-CoA reductase and LDL-receptor
genes in cells from dhcr7/ mice (i.e. a mouse model for
SLOS), which are similar to the mRNA levels in control mice
[31].
Another scenario is that the sterol intermediates downregu-
late sterol synthesis via a posttranslational regulatory mecha-
nism. Both in cells of SLOS patients and in the dhcr7/
mouse, 7-dehydrocholesterol was found to be a potent inhibi-
tor of HMG-CoA reductase at the protein but not the tran-
scriptional level reducing the rates of sterol biosynthesis
[31,32]. Although in one in vitro study, it was shown that 7-
dehydrocholesterol, or a derivative thereof, accelerates the
degradation of HMG-CoA reductase [31], another study
reported that 7-dehydrocholesterol as well zymosterol, zymos-
tenol, lathosterol and desmosterol did not promote ubiquitina-
tion and degradation of HMG-CoA reductase [26].7. Cholesterol and embryogenesis
The overall clinical presentation of patients with a choles-
terol biosynthesis defect is consistent with an important role
for cholesterol in human embryogenesis and development.
This has been attributed to cholesterol’s role in hedgehog sig-
naling [33,34]. The hedgehog proteins, including Sonic, Indian
and Dessert hedgehog, are secreted signaling molecules (mor-
phogens), which have been implicated in diﬀerent embryonic
patterning processes, many of which are disturbed in patients
with one of the cholesterol biosynthesis defects [33,34].
The hedgehog proteins are subject to an autocatalytic cleav-
age process mediated by their C-terminal domain, during
which cholesterol becomes covalently attached to the N-termi-
nal signaling domain. The cholesterol adduction enables the
insertion of the N-terminal domain in the plasma membrane,
where it interacts with its receptor Patched. This interaction
may be promoted by the cholesterol moiety, because Patched
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Patched has also been observed in the absence of cholesterol.
The interaction with hedgehog alters Patched’s interaction
with another membrane protein called Smoothened and re-
leases Smoothened’s repression of the hedgehog protein signal
transduction pathways, resulting in transcriptional activation
of genes involved in embryonic patterning and morphogenesis
[33,34].
It is assumed that perturbations of the hedgehog protein sig-
nal transduction pathways are responsible for many of the
congenital abnormalities associated with the cholesterol bio-
synthesis defects. Indeed, in contrast to cholesterol, 7-dehydro-
cholesterol fails to stimulate the Sonic hedgehog signaling
pathway [33]. Initially it was hypothesized that either the low
levels of cholesterol, the presence of aberrant sterols or both
would disrupt the autocatalytic processing of the hedgehog
proteins. However, Sonic hedgehog is also normally processed
with 7-dehydrocholesterol and desmosterol in an in vitro assay
as well as upon expression in embryonic ﬁbroblasts derived
from a Smith–Lemli–Opitz syndrome or a lathosterolosis
mouse model [35]. Based on these ﬁndings and because
Patched contains a sterol-sensing domain, it then was hypoth-
esized that impaired hedgehog signaling may be due to changes
in the intracellular sterol concentrations. Indeed, it was found
that the response to Sonic hedgehog in the mouse SLO and
lathosterolosis embryonic ﬁbroblasts is impaired at the level
of Smoothened and caused by decreased sterol levels rather
than by the accumulation of abnormal sterol intermediates
[35]. Yet, it can still not be excluded that the interaction of
the sterol-modiﬁed hedgehog signaling domain with Patched
is less eﬃcient with one of the accumulating sterol precursors
than with cholesterol. An interesting ﬁnding in this respect is
the association of the cholesterol-modiﬁed hedgehog signaling
domain, Patched and Smoothened with raft lipid microdo-
mains [36]. In addition to the possibility that the eﬃciency of
signaling might depend on the localization of the hedgehog sig-
naling domain to rafts, the association may also be required
for the spatially restricted subcellular and tissue distribution
of the domain. The formation of such lipid rafts is highly
dependent on the structure of the sterol component, which
promotes the packing with lipids having saturated acyl chains
(e.g. sphingolipids), and 7-dehydrocholesterol, the accumulat-
ing sterol in Smith–Lemli–Opitz syndrome, is signiﬁcantly
more strongly lipid raft-promoting than cholesterol [37]. Thus,
both the overall sterol levels and the composition of these may
have eﬀects on the formation and/or functioning of lipid rafts
and consequently on that of its protein components [38].
Hence, it may well be possible that in patients with a choles-
terol biosynthesis defect, the formation of rafts and/or the
localization of the sterol-modiﬁed hedgehog signaling do-
mains, Patched and/or Smoothened to these rafts is disturbed
leading to impaired hedgehog signaling.8. (Maternal) Cholesterol in embryogenesis and development
Most clinical features associated with the cholesterol biosyn-
thesis defects are of early fetal and embryogenic origin. The
growing fetus has a high demand for cholesterol, which during
early pregnancy is maternally derived whereas during late
pregnancy the fetus entirely relies on its own high cholesterol
biosynthesis capacity [39]. A strong indication for transfer ofmaternal cholesterol to the fetus comes from the observation
that fetuses with SLOS, who have two null mutations in the
DHCR7 gene and thus cannot synthesize cholesterol, still have
low amounts of cholesterol in their tissues and blood. In fact,
the amount of maternal (LDL) cholesterol that is transported
to the fetus across the placenta may be an important denomi-
nator for the severity of the pathology arising during early
stages of embryonic development in fetuses with a cholesterol
biosynthesis defect. Because these fetuses have low cholesterol
synthesis rates, the fetal cholesterol concentrations are more
dependent on and in fact have been shown to correlate with
maternal cholesterol concentrations as is the clinical severity
in these fetuses [39,40]. Furthermore, the clinical presentation
of patients with SLOS is more severe in patients whose moth-
ers carry the apo e2 allele than in patients whose mothers do
not carry this allele [41]. Apo e2-containing LDL cholesterol
binds less eﬀective to the LDL receptor, decreasing the trans-
port eﬃciency of maternal LDL cholesterol to the fetus.
The contribution of maternal cholesterol to fetal cholesterol
homeostasis is more prominent in rodents [39] and appears
essential for early embryonic development, as also evident
from the lethal fetal phenotype of mice with defects in placen-
tal cholesterol transport [42]. Moreover, although in general
they display similar severe symptoms as their human counter-
parts, mice with defects in the postsqualene part of cholesterol
biosynthesis pathway often survive to term [14,31,43], whereas
mice with a defect in the pre-squalene part do not [44]. A strik-
ing example of this are the two desmosterolosis mouse models,
which both were generated by knocking-out the dhcr24 gene.
In contrast to the few patients known with this defect, one
mouse model had a relatively mild phenotype [45] whereas
the other mouse model in another genetic background showed
a lethal phenotype [46]. Sterol analysis of plasma and liver of
3-months-old dhcr24/ mice with the mild phenotype revealed
that desmosterol accounted for >90% of all the sterols. How-
ever, sterol analysis of dhcr24/ embryos showed that 60%
and 30% of the total sterols comprised of cholesterol at gesta-
tion days 11.5 and 17.5, respectively, which can only be of
maternal origin, because the fetus is incapable of converting
desmosterol into cholesterol [45]. Whereas the maternally de-
rived cholesterol may allow embryonic development of the
dhcr24/ fetuses per se, the relative mild phenotype and the
occurrence of rather normal total sterol plasma levels of
the 3-months-old dhrc24/ mice indicates that desmosterol
may substitute for cholesterol in selected processes, including
the maintenance of sterol homeostasis via SREBP as discussed
above. The lethal phenotype of the second mouse model has
been attributed to the marked diﬀerence in cholesterol absorp-
tion in mice with diﬀerent genetic backgrounds [46]. The lower
cholesterol absorption in the latter genetic background may
not allow for suﬃcient maternal cholesterol transport to the
fetus.9. Conclusions
The complicated clinical phenotype of patients aﬀected with
one of the inherited defects of cholesterol biosynthesis, includ-
ing the multiple aﬀected developmental processes, underlines
the important roles of cholesterol and its biosynthetic path-
way in a large variety of cellular processes that have become
apparent in the past decades. The etiology underlying the
5448 H.R. Waterham / FEBS Letters 580 (2006) 5442–5449pathophysiology associated with these defects may involve
multiple aﬀected processes, ranging from defective regulation
of the isoprenoid/cholesterol biosynthesis pathway to defects
in developmental processes, which depend on speciﬁc isopre-
noids/sterols produced by the pathway. These processes are
most probably defective as a consequence of the combined ef-
fect of low cholesterol levels, elevated (teratogenic) levels of
sterol intermediates and a variable ability of these sterol inter-
mediates to functionally substitute for cholesterol in choles-
terol-dependent pathways.
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